Anna Suk‐Fong Lok – 15 November 2018 – Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, interferons (IFNs) and nucleos(t)ide analogues (NAs), have been approved. These treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. However, these treatments do not eliminate the virus, and the risk of HCC remains.

Débora Raquel Benedita Terrabuio, Marcio Augusto Diniz, Lydia Teofilo de Moraes Falcão, Ana Luiza Vilar Guedes, Larissa Akeme Nakano, Andréia Silva Evangelista, Fabiana Roberto Lima, Clarice Pires Abrantes‐Lemos, Flair José Carrilho, Eduardo Luiz Rachid Cancado – 14 November 2018 – Between 50% and 86% of patients with autoimmune hepatitis (AIH) relapse after immunosuppression withdrawal; long‐term immunosuppression is associated with increased risk of neoplasias and infections.

Maria G. Cardona‐Gonzalez, Jason D. Goldman, Lawrence Narayan, Diana M. Brainard, Kris V. Kowdley – 14 November 2018 – There are limited data on direct‐acting antiviral (DAA) treatment options for previously treated patients with recurrent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs.

This lecture summarizes the current approach to understanding NASH pathogenesis, and how to translate recent advances into routine clinical care. Beginning with an overview of key pathogenic steps in development and progression of NASH, the program will also cover different therapeutic approaches for specific subsets of patients with NASH and related complications, and risk stratification of patients with respect to clinical outcomes.Michael W. Fried (Moderator) Arun J. Sanyal Arun J.

This session is designed to complement the highly-regarded, Hepatitis and Clinical Hepatology Debriefs, and will review key highlights from The Liver Meeting®.Jorge A. Bezerra (Moderator) Mary E. McCarthy Rinella Mary E. Rinella, MD is a Professor of Medicine at Northwestern University Feinberg School of Medicine and is the Director of the Northwestern Fatty Liver Program.

This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.Jorge A. Bezerra (Moderator) Jordan J. Feld Jordan J. Feld, MD, MPH, FAASLD attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis.

This session provides a summary of the clinical highlights from The Liver Meeting®.Jorge A. Bezerra (Moderator) K. Rajender Reddy

Babak Torabi Sagvand, Katelyn Edwards, Bo Shen – 13 November 2018 – The prevalence polyps (GBPs) in the general population has been estimated to be approximately 5%, with up to 10% of these being dysplastic or malignant. Previous studies have suggested that patients with primary sclerosing cholangitis (PSC) have increased frequency of GBPs. However, data on the prevalence, risk factors, and outcome of GBPs in these patients are sparse. This case‐control study investigates the frequency, risk factors, and outcome of GBPs in patients with PSC.

HCC is the fifth most common cancer and the third cause of cancer-related deaths worldwide. The underlying liver disease that ultimately leads to HCC varies throughout the world. Identifying the population at risk for HCC is critical in order to implement preventive strategies to reduce the burden of the disease. Moreover, identifying the population at risk will facilitate the use of surveillance programs.

Patients with underlying chronic liver disease (CLD) may develop drug-induced liver injury during clinical care or in clinical trials, and it is associated with poor outcomes. This lecture discusses medications and herbal agents that are commonly implicated in DILI, risk factors, strategies for  monitoring patients in clinical trials, guidelines for adjudicating suspected DILI events and outcomes associated with DILI in CLD.Mark I.